Recent Therapeutics Policies of Arthritis Rheumatoid (part I)
DOI:
https://doi.org/10.30649/obj.v1i1.2Keywords:
conventional, DMARDs, biological agentsAbstract
Therapy in RA has undergone many advances today and in line with knowledge
of the pathogenesis of RA, the current therapeutic goal is to alter the journey and control
the activity of RA disease. Several groups of drugs have been used in RA therapy
including non-steroidal anti-inflammatory drugs (NSAIDs), conventional diseasemodifying antirheumatic drugs (DMARDs) as well as biological agents (bDMARD),
glucocorticoids and anti-pain medicines. In recent years, the development of biological
agents that have specific targets for inflammatory mediators such as interleukin (IL) -
1, IL-6 and Tumor Necrosis Factor (TNF) suggests a potent therapeutic effect on RA.
In this article will be presented the latest biological agents as the latest therapy on RA.
References
Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al.
EULAR recommendations for the management of rheumatoid arthritis with
synthetic and biological disease-modyfing antirheumatic drugs: 2013 update. Ann
Rheum Dis. 2013; 13: 1-18.
Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al.
Canadian Rheumatology Association recommendations for pharmacological
management of rheumatoid arthritis with traditional and biologic diseasemodifying antirheumatic drugs. J Rheumatol. 2012;39:1559–82.
Iskandar A, Wachjudi RG. Diagnosis dan Penatalaksanaan Artritis Reumatoid,
Himpunan Makalah Lengkap Rheumatologi Klinik Bandung. Bandung: Pusat
Informasi Ilmiah Departemen Ilmu Penyakit Dalam FK Universitas Padjajaran,
: 309-340.
Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment
response in rheumatoid arthritis based on the simplified and the clinical disease
activity index. Ann Rheum Dis 2012;71:1190–6.
Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, Oosterhout MV, Harbers
JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at
achieving remission: the IMPROVED study. Ann Rheum Dis. 2013;374:459–66.
Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs,
glucocorticoids, and biologic agents on radiographic progression in rheumatoid
arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled
studies, including 112 comparisons. Arthritis Rheum. 2010;62:2852–63.
Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. LowDose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for
Early Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2012;156:329–
Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients
with continued conventional therapy for moderate disease activity—the early RA
network (ERAN). J Rheumatology. 2011;50:926–31.
Cash J.M, Klippel J.H,. Second-Line Drug Therapy for Rheumatoid Arthtritis.
New England J Medicine 1994;330 (19):1368–1376.
Strangfeld A, Hierse F, Kekow J, Hinueber UV, Tony HP, Dockhorn R, et al.
Comparative effectiveness of tumour necrosis factor alpha inhibitors in
combination with either methotrexate or leflunomide. Ann Rheum Dis.
;68:1856–62.
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al.
Association between the initiation of anti-tumor necrosis factor therapy and the
risk of herpes zoster. JAMA. 2013;309:887–95.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis
factor antagonist therapy and lymphoma development: Twentysix cases reported
to the food and drug administration. Arthritis Rheum. 2002;46(12):3151–3158.
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, KaipiainenSeppanen O, et al. Infliximab for 6 months added on combination therapy in early
rheumatoid arthritis: 2-year results from an investigator-initiated, randomised,
double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis.
;72:851–7.
van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand
E, et al. Addition of infliximab compared with addition of sulfasalazine and
hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis
(Swefot trial): 1-year results of randomised trial. Lancet. 2009;374:459–66.
Smolen JS, Han C, Van der Heijde DM, Emery P, Bathon JM, Keystone E, et al.
Radiographic changes in rheumatoid arthritis patients attaining different disease
activity states with methotrexate monotherapy and infliximab plus methotrexate:
the impacts of remission and TNF-blockade. Ann Rheum Dis. 2008;68:823–7.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al.
Therapeutic effect of the combination of etanercept and methotrexate compared
with each treatment alone in patients with rheumatoid arthritis: double-blind
randomised controlled trial. Lancet. 2004;363:675–81.
Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, Clair EW, et al. A
randomized comparative effectiveness study of oral triple therapy versus
etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment
of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824–
Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission
with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in
patients with early rheumatoid arthritis who achieved remission with etanercept
and methotrextate: the PRIZE study. Ann Rheum Dis 2013;72(Suppl 3):399-415.
Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al.
Clinical, functional and radiographic consequences of achieving stable low disease
activity and remission with adalimumab plus methotrexate or methotrexate alone
in early rheumatoid arthritis: 26-week results from the randomised, controlled
OPTIMA study. Ann Rheum Dis 2013;72:64–71.
Burmester G, Kivitz A, Kupper H, Arulmani U, Florentinus S, Goss SL, et al.
Efficacy and safety of ascending methotrexate dose in combination with
adalimumab: results from the CONCERTO trial. Ann Rheum Dis. 2013;72(Suppl
:72-92.
Fleischmann R, van Vollenhoven RF, Smolen JS, et al. Long-Term Outcomes of
Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate
Compared with Methotrexate Alone Following a Targeted Treatment Approach.
Arthritis Rheum. 2012;64(Suppl):S335–6.
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al.
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody,
injected subcutaneously every four weeks in methotrexate-naive patients with
active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter,
randomized, double-blind, placebo-controlled study of golimumab before
methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis
Rheum. 2009;60(8): 2272–2283
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL. Golimumab in patients
with active rheumatoid arthritis after treatment with tumor necrosis factor alpha
inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebocontrolled, phase III trial. Lancet. 2009;374:210–221.
Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use
of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909–
Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk
factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum.
;62:2625–32.
Schiff M, Fleischmann R, Weinblatt M, Valente R, Heijde D, Citera G, et al. Head
to head comparison of subcutaneus abatacept versus adalimumab for rheumatoid
arthritis: Findings of phase IIIb, multinational, prospective, randomised study. Ann
Rheum Dis. 2013;71(3):28-38.
Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety
and efficacy of the selective costimulation modulator abatacept in patients with
rheumatoid arthritis receiving background methotrexate: a 5-year extended phase
IIB study. J Rheumatol. 2009;36(4):736–742.
Gabay C, Emery P, van VR, Vollenhoven R, Dikranian A, Alten R, et al.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of
rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4
trial. Lancet. 2013;381:1541–50.
Morel J, Duzanski MO, Cantagrel A, Combe B, Dougados M, Flipo RM, et al.
Prospective follow-up of tocilizumab treatment in 1100 patients with refractory
rheumatoid arthritis: tolerance data from the french registry regate (registry–
roactemra). Ann Rheum Dis 2013;72 (3):456-470.
Burmester GR, Rigby W, van Vollenhoven R, Kay RF, Rubbert-Roth J, Kelman
A, et al. Tocilizumab (TCZ) in combination and monotherapy versus methotrexate
(MTX) in MTX-naive patients (pts) with early rheumatoid arthritis (RA): clinical
and radiographic outcomes from a randomised, placebo-controlled trial. Ann
Rheum Dis. 2013;72(l):41-63.
Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, et al. Efficacy and
safety of pamapimod in patients with active rheumatoid arthritis receiving stable
methotrexate therapy. Ann Rheum Dis. 2010;69(2):364–367.
Genovese MC, Kavanaugh A, Peterfy CG, Magilavy D. An oral syk kinase
inhibitor in the treatment of rheumatoid arthritis (RA): a 3 month randomized
placebo controlled phase 2 study in patients with active RA who had failed biologic
agents. ACR. 2009; 70:909–20.
Lee EB, Fleischmann RM, Hall S, et al. Radiographic, Clinical and Functional
Comparison of Tofacitinib Monotherapy Versus Methotrexate in MethotrexateNave Patients with Rheumatoid Arthritis. Arthritis Rheum 2012;64(Suppl): S1049.
Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of
anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA.
;309:887–95.
Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control
for rheumatoid arthritis (the TICORA study): A singleblind randomised controlled
trial. Lancet. 2004;364(9430):263–269.
Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients
with continued conventional therapy for moderate disease activity—the early RA
network (ERAN). J Rheumatology. 2011;50:926–31.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Oceana Biomedicina Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
